Explore /
Poster
/ A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.

A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.

Authors

Aaron Richard Hansen

Princess Margaret Cancer Centre, Toronto, ON, Canada

Aaron Richard Hansen , Geoffrey Shapiro , Khanh T Do , Rajiv Kumar , Juan Martin-Liberal , Celestia S. Higano , Kari Braun Wisinski , Emma Jane Dean , Elisabeth I. Heath , Dana E. Rathkopf , Mark David Linch , Simon T Barry , Wolfram Brugger , Elza De Bruin , Steve Colebrook , Teresa Klinowska , Patrick D Mitchell , Ganesh Moorthy , Johann S. De Bono , Lillian L. Siu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT01884285

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2570)

DOI

10.1200/JCO.2017.35.15_suppl.2570

Abstract #

2570

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Annual Meeting

$Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.$